Fundraising Fox
DMC Biotechnologies
Boulder, US · Founded 2014 · 42 employees on LinkedIn · 10 known investors
Find your way into DMC Biotechnologies
Sign up to see every warm intro you have to DMC Biotechnologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the DMC Biotechnologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols. It serves specialty chemical, nutraceutical, and industrial customers seeking sustainable, cost-competitive alternatives to conventional chemical supply chains.
Founders & leadership
DMC Biotechnologies was founded in 2014 by Matthew Lipscomb.
Board
Investors · 10
How we know: funding news · sofinnovapartners.com · Not right? Tell us
How we know: CIBUS ENTERPRISE FUND II LP's portfolio page · Not right? Tell us
How we know: Sofinnova Partners's portfolio page · funding news · sofinnovapartners.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · sofinnovapartners.com · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Also in the syndicate · 4
Reported raises · per SEC filings
Form D private placements$48.1M disclosed across 8 rounds · 2018–2025
▶$1.4MraisedDec 2025 · 7 investors · BiotechnologyRule 506(b)
- Josh YelenExecutive Officer
- Josko BobanovicDirector
- Rob van der MeijDirector
- K'Lynne JohnsonDirector
- Alastair CooperDirector
- Jim FlattExecutive Officer, Director
- Doug CameronDirector
- Matthew LipscombDirector
- Offering amount
- $2.5M
- Amount sold
- $1.4M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$904.5KraisedDec 2025 · 4 investors · BiotechnologyRule 506(b)
- Rob van der MeijDirector
- Josh YelenExecutive Officer
- Alastair CooperDirector
- K'Lynne JohnsonDirector
- Matthew LipscombDirector
- Jim FlattExecutive Officer, Director
- Doug CameronDirector
- Josko BobanovicDirector
- Offering amount
- $1.7M
- Amount sold
- $904.5K
- First sale
- Oct 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.8MraisedApr 2025 · 9 investors · BiotechnologyRule 506(b)
- Doug CameronDirector
- Rob van der MeijDirector
- K'Lynne JohnsonDirector
- Josh YelenExecutive Officer
- Alastair CooperDirector
- Matthew LipscombDirector
- Jim FlattExecutive Officer, Director
- Josko BobanovicDirector
- Offering amount
- $10M
- Amount sold
- $4.8M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$66.7KraisedAug 2022 · 1 investors · BiotechnologyRule 506(b)
- Doug CameronDirector
- Josko BobanovicDirector
- Carolyn FritzDirector
- Michael D. LynchDirector
- Matthew LipscombExecutive Officer, Director
- Rob van der MeijDirector
- Ashley JenkinsExecutive Officer
- Alastair CooperDirector
- Offering amount
- $66.7K
- Amount sold
- $66.7K
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$33.8MraisedDec 2021 · 12 investors · BiotechnologyRule 506(b)
- Doug CameronDirector
- Alastair CooperDirector
- Rob van der MeijDirector
- Josko BobanovicDirector
- Matthew LipscombExecutive Officer, Director
- Carolyn FritzDirector
- Michael D. LynchDirector
- Offering amount
- $43.5M
- Amount sold
- $33.8M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$22.4KraisedJan 2021 · 1 investors · BiotechnologyRule 506(b)
- Josko BobanovicDirector
- Rob van der MeijDirector
- Carolyn FritzDirector
- Michael D. LynchDirector
- Matthew LipscombExecutive Officer, Director
- Doug CameronDirector
- Offering amount
- $22.4K
- Amount sold
- $22.4K
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$4.6MraisedJun 2019 · 3 investors · BiotechnologyRule 506(b)
- Rob van der MeijDirector
- Josko BobanovicDirector
- Michael D. LynchDirector
- Carolyn FritzDirector
- Matthew LipscombExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $4.6M
- First sale
- Jun 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.5MraisedMar 2019 · 3 investors · BiotechnologyRule 506(b)
- Michael D. LynchDirector
- Rob van der MeijDirector
- Matthew L. LipscombExecutive Officer, Director
- Carolyn FritzDirector
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2017 | $600K |
| Department of Agriculture (USDA) | Phase I | 2017 | $100K |
| National Science Foundation | Phase ISTTR | 2016 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does DMC Biotechnologies do?
- DMC Biotechnologies is a U.S.-based biomanufacturer that uses precision fermentation and its Dynamic Metabolic Control platform to produce bio-based specialty chemicals and ingredients, such as L-alanine and fermented inositols. It serves specialty chemical, nutraceutical, and industrial customers seeking sustainable, cost-competitive alternatives to conventional chemical supply chains.
- Who founded DMC Biotechnologies?
- DMC Biotechnologies was founded by Matthew Lipscomb in 2014.
- Who are DMC Biotechnologies's investors?
- DMC Biotechnologies's investors include Breakthrough Energy Ventures, CIBUS ENTERPRISE FUND II LP, Sofinnova Partners, Boulder Ventures, Capricorn Venture Partners, Michelin Ventures.
- How much funding has DMC Biotechnologies raised?
- DMC Biotechnologies has disclosed $48.1M raised across 8 rounds.
- Where is DMC Biotechnologies headquartered?
- DMC Biotechnologies is headquartered in Boulder, US.